TapewireFind a company

person · Reporting owner

Climaco John M

Disclosed activity across 4 companies

Tapewire entity
72888
SEC CIK
0001546797

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
CNS Pharmaceuticals, Inc.CNSP · Entity 8048Director · Chief Executive OfficerNovember 17, 2025November 19, 2025
Moleculin Biotech, Inc.MBRX · Entity 7886DirectorNovember 12, 2025November 14, 2025
STAR EQUITY HOLDINGS, INC.DRAD · Entity 76212DirectorAugust 16, 2019August 19, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CNS Pharmaceuticals, Inc.

Report date November 17, 2025 · Filed November 19, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $30.00 · Expires 2035-11-17Direct9,761 Reported balance After 2025-11-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2025-11-17 · Grant · Acquired 9,761 · Balance 9,761

F1: The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on March 11, 2025 (the "Grant Date"), subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025.

F3: Issued in connection with the reporting person's employment with the Company.

F2: The options set forth in the table vest as follows: 50% on the six-month anniversary of the Grant Date, 25% on the 12-month anniversary of the Grant Date, and 25% on the 18-month anniversary of the Grant Date, subject to the reporting person's continued employment on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on March 11, 2025 (the "Grant Date"), subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025.

F2: The options set forth in the table vest as follows: 50% on the six-month anniversary of the Grant Date, 25% on the 12-month anniversary of the Grant Date, and 25% on the 18-month anniversary of the Grant Date, subject to the reporting person's continued employment on each vesting date.

F3: Issued in connection with the reporting person's employment with the Company.

Moleculin Biotech, Inc.

Report date November 12, 2025 · Filed November 14, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.49 · Expires 2035-11-12Direct165,169 Reported balance After 2025-11-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2025-11-12 · Grant · Acquired 150,000 · Balance 165,169

F2: The options were issued in connection with the reporting person's Board of Director service to the Company.

F1: The options set forth in this table vest on November 12, 2026, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The options set forth in this table vest on November 12, 2026, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.

F2: The options were issued in connection with the reporting person's Board of Director service to the Company.

STAR EQUITY HOLDINGS, INC.

Report date August 16, 2019 · Filed August 19, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Restricted Stock UnitSEC Table II · derivative / convertible securityDirect2,250 Reported balance After 2019-08-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2019-08-16 · Grant · Acquired 2,250 · Balance 2,250

F1: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock.

F2: One hundred percent (100%) of the Restricted Stock Units are scheduled to vest on the one (1) year anniversary of August 16, 2019, subject to the Reporting Person continuing to be a service provider through such date.

Common StockSEC Table I · non-derivativeDirect6,910 Reported balance Holding disclosure · report date 2019-08-16 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 6,910

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock.

F2: One hundred percent (100%) of the Restricted Stock Units are scheduled to vest on the one (1) year anniversary of August 16, 2019, subject to the Reporting Person continuing to be a service provider through such date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

BIRNER DENTAL MANAGEMENT SERVICES INC

Report date January 14, 2019 · Filed January 14, 2019

Section 16 reporting ended · disclosed 2019-01-14. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2019-01-14 transaction · row 1
1 source row

Row 1 · 2019-01-14 · Disposition to issuer · Disposed 4,000 · Balance 0

F1: Disposed of as a result of a merger pursuant to the previously announced Agreement and Plan of Merger, dated as of October 3, 2018 (the "Merger Agreement"), by and among the issuer, Mid-Atlantic Dental Services Holdings, LLC, and Bronco Acquisition, Inc., in exchange for, on a per share basis, (i) $10.62 in cash and (ii) a contingent value right entitling the holder thereof to receive up to $0.13 per share that may become payable after 18 months in accordance with the terms of the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of as a result of a merger pursuant to the previously announced Agreement and Plan of Merger, dated as of October 3, 2018 (the "Merger Agreement"), by and among the issuer, Mid-Atlantic Dental Services Holdings, LLC, and Bronco Acquisition, Inc., in exchange for, on a per share basis, (i) $10.62 in cash and (ii) a contingent value right entitling the holder thereof to receive up to $0.13 per share that may become payable after 18 months in accordance with the terms of the Merger Agreement.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
November 17, 2025 Filed Nov 19, 2025 17:00 UTC CNS Pharmaceuticals, Inc. CNSP · Entity 8048 GrantOption to purchase common stock · Derivative 9,761 $0.00 Strike: $30.00 $0.00
Disclosure

SEC source: 0001683168-25-008564 · ownership.xml · derivative · entry 1

Climaco John M · CIK 0001546797 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,761

Underlying: Common Stock · 9,761 shares

Expires 2035-11-17

F1 · date: The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on March 11, 2025 (the "Grant Date"), subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025.

F3 · price: Issued in connection with the reporting person's employment with the Company.

F2 · derivative.exercise_date: The options set forth in the table vest as follows: 50% on the six-month anniversary of the Grant Date, 25% on the 12-month anniversary of the Grant Date, and 25% on the 18-month anniversary of the Grant Date, subject to the reporting person's continued employment on each vesting date.

Read SEC document
November 12, 2025 Filed Nov 14, 2025 21:05 UTC Moleculin Biotech, Inc. MBRX · Entity 7886 GrantStock Options (right to buy) · Derivative 150,000 Not disclosed Strike: $0.49 Not disclosed
Disclosure

SEC source: 0001437749-25-035170 · rdgdoc.xml · derivative · entry 1

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,169

Underlying: Common Stock · 150,000 shares

Expires 2035-11-12

F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company.

F1 · derivative.exercise_date: The options set forth in this table vest on November 12, 2026, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.

Read SEC document
November 04, 2024 Filed Nov 7, 2024 01:04 UTC Moleculin Biotech, Inc. MBRX · Entity 7886 GrantStock option (right to buy) · Derivative 10,000 Not disclosed Strike: $2.45 Not disclosed
Disclosure

SEC source: 0001437749-24-033708 · rdgdoc.xml · derivative · entry 1

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,169

Underlying: Common Stock · 10,000 shares

Expires 2034-11-04

F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company.

F1 · derivative.exercise_date: The options set forth in this table vest through April 2025, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.

Read SEC document
April 08, 2024 Filed Apr 10, 2024 21:50 UTC CNS Pharmaceuticals, Inc. CNSP · Entity 8048 GrantRestricted Stock Units · Derivative 83,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001683168-24-002284 · ownership.xml · derivative · entry 2

Climaco John M · CIK 0001546797 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 559,533

Underlying: Common Stock · 83,000 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Company common stock.

F2 · price: Issued in connection with the reporting person's employment with the Company.

F4 · derivative.exercise_date: The restricted stock units set forth in the table vest in eight equal quarterly installments over two years.

F4 · derivative.expiration_date: The restricted stock units set forth in the table vest in eight equal quarterly installments over two years.

Read SEC document
April 08, 2024 Filed Apr 10, 2024 21:50 UTC CNS Pharmaceuticals, Inc. CNSP · Entity 8048 GrantOption to purchase common stock · Derivative 83,000 Not disclosed Strike: $0.26 Not disclosed
Disclosure

SEC source: 0001683168-24-002284 · ownership.xml · derivative · entry 1

Climaco John M · CIK 0001546797 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 476,533

Underlying: Common Stock · 83,000 shares

Expires 2034-04-08

F2 · price: Issued in connection with the reporting person's employment with the Company.

F1 · derivative.exercise_date: The options set forth in the table vest in 36 equal monthly installments over three years.

Read SEC document
February 01, 2024 Filed Feb 6, 2024 10:27 UTC CNS Pharmaceuticals, Inc. CNSP · Entity 8048 GrantSeries B Warrant to purchase common stock · Derivative 166,666 Not disclosed Strike: $0.30 Not disclosed
Disclosure

SEC source: 0001683168-24-000705 · ownership.xml · derivative · entry 3

Climaco John M · CIK 0001546797 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 393,533

Underlying: Common Stock · 166,666 shares

Expires 2025-10-01

F1 · price: The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.

Read SEC document
February 01, 2024 Filed Feb 6, 2024 10:27 UTC CNS Pharmaceuticals, Inc. CNSP · Entity 8048 GrantSeries A Warrant to purchase common stock · Derivative 166,666 Not disclosed Strike: $0.30 Not disclosed
Disclosure

SEC source: 0001683168-24-000705 · ownership.xml · derivative · entry 2

Climaco John M · CIK 0001546797 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 226,867

Underlying: Common Stock · 166,666 shares

Expires 2029-02-01

F1 · price: The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.

Read SEC document
February 01, 2024 Filed Feb 6, 2024 10:27 UTC CNS Pharmaceuticals, Inc. CNSP · Entity 8048 PurchaseCommon stock 166,666 $0.30 $49,999.80
Disclosure

SEC source: 0001683168-24-000705 · ownership.xml · nonDerivative · entry 1

Climaco John M · CIK 0001546797 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 215,676

F1 · price: The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.

Read SEC document
August 16, 2023 Filed Aug 16, 2023 16:01 UTC CNS Pharmaceuticals, Inc. CNSP · Entity 8048 PurchaseCommon Stock 2,750 $1.80 $4,944.50
Disclosure

SEC source: 0001683168-23-005828 · ownership.xml · nonDerivative · entry 1

Climaco John M · CIK 0001546797 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,010

Read SEC document
May 25, 2023 Filed May 26, 2023 21:16 UTC Moleculin Biotech, Inc. MBRX · Entity 7886 GrantStock option (right to buy) · Derivative 15,000 Not disclosed Strike: $0.62 Not disclosed
Disclosure

SEC source: 0001437749-23-016002 · rdgdoc.xml · derivative · entry 1

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,501

Underlying: Common Stock · 15,000 shares

Expires 2033-05-25

F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company.

F1 · derivative.exercise_date: The options set forth in this table vest on the earlier of one year from the date of the Company's 2023 annual meeting of stockholders or on the next annual meeting of stockholders, subject to the grantee's continued service on the Company's Board of Directors on such vesting date.

Read SEC document
April 28, 2023 Filed May 1, 2023 18:59 UTC CNS Pharmaceuticals, Inc. CNSP · Entity 8048 Exercise / conversionRestricted Stock Units · Derivative 1,250 Not disclosed Not disclosed
Disclosure

SEC source: 0001683168-23-002830 · ownership.xml · derivative · entry 2

Climaco John M · CIK 0001546797 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,201

Underlying: Common Stock · 1,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · price: On April 28, 2022, the reporting person received 20,000 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors.

F2 · derivative.exercise_date: On April 28, 2022, the reporting person received 20,000 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors.

F2 · derivative.expiration_date: On April 28, 2022, the reporting person received 20,000 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors.

Read SEC document
April 28, 2023 Filed May 1, 2023 18:59 UTC CNS Pharmaceuticals, Inc. CNSP · Entity 8048 Exercise / conversionCommon Stock 1,250 Not disclosed Not disclosed
Disclosure

SEC source: 0001683168-23-002830 · ownership.xml · nonDerivative · entry 1

Climaco John M · CIK 0001546797 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,260

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
April 12, 2023 Filed Apr 14, 2023 16:20 UTC CNS Pharmaceuticals, Inc. CNSP · Entity 8048 PurchaseCommon Stock 15,000 $0.69 $10,408.50
Disclosure

SEC source: 0001683168-23-002405 · ownership.xml · nonDerivative · entry 1

Climaco John M · CIK 0001546797 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,010

F1 · price: This transaction was executed in multiple trades at prices ranging from $0.677 to $0.70. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
March 29, 2023 Filed Mar 31, 2023 19:28 UTC CNS Pharmaceuticals, Inc. CNSP · Entity 8048 GrantRestricted Stock Units · Derivative 16,467 Not disclosed Not disclosed
Disclosure

SEC source: 0001683168-23-002096 · ownership.xml · derivative · entry 1

Climaco John M · CIK 0001546797 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,451

Underlying: Common stock · 16,467 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one shares of Issuer common stock.

F3 · price: Issued in connection with the reporting person's employment with the Company.

F2 · derivative.exercise_date: The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 50% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $6.00 (subject to pro rata adjustment for stock splits or similar events); and (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $24.00 (subject to pro rata adjustment for stock splits or similar events).

F2 · derivative.expiration_date: The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 50% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $6.00 (subject to pro rata adjustment for stock splits or similar events); and (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $24.00 (subject to pro rata adjustment for stock splits or similar events).

Read SEC document
June 20, 2022 Filed Jun 22, 2022 23:04 UTC Moleculin Biotech, Inc. MBRX · Entity 7886 GrantStock option (right to buy) · Derivative 15,000 Not disclosed Strike: $1.49 Not disclosed
Disclosure

SEC source: 0001437749-22-015662 · rdgdoc.xml · derivative · entry 2

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,501

Underlying: Common Stock · 15,000 shares

Expires 2032-06-20

F3 · price: The options were issued in connection with the reporting person's Board of Director service to the Company.

F2 · derivative.exercise_date: The options set forth in this table vest on the earlier of one year from the date of the Company's 2022 annual meeting of stockholders or on the date of the next annual meeting of stockholders, subject the grantee's continued service on the Company's Board of Directors on each vesting date.

Read SEC document
June 20, 2022 Filed Jun 22, 2022 23:04 UTC Moleculin Biotech, Inc. MBRX · Entity 7886 GrantStock option (right to buy) · Derivative 23,333 Not disclosed Strike: $1.49 Not disclosed
Disclosure

SEC source: 0001437749-22-015662 · rdgdoc.xml · derivative · entry 1

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,501

Underlying: Common Stock · 23,333 shares

Expires 2032-06-20

F3 · price: The options were issued in connection with the reporting person's Board of Director service to the Company.

F1 · derivative.exercise_date: The options set forth in this table vest in three equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.

Read SEC document
April 28, 2022 Filed Apr 29, 2022 17:11 UTC CNS Pharmaceuticals, Inc. CNSP · Entity 8048 GrantRestricted Stock Units · Derivative 600,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001683168-22-003053 · ownership.xml · derivative · entry 1

Climaco John M · CIK 0001546797 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,349,500

Underlying: Common Stock · 600,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one shares of Issuer common stock.

F3 · price: Issued in connection with the reporting person's employment with the Company.

F2 · derivative.exercise_date: The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors.

F2 · derivative.expiration_date: The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors.

Read SEC document
March 07, 2022 Filed Mar 8, 2022 08:30 UTC CNS Pharmaceuticals, Inc. CNSP · Entity 8048 GrantCommon Stock 35,000 $0.28 $9,835.00
Disclosure

SEC source: 0001683168-22-001495 · ownership.xml · nonDerivative · entry 1

Climaco John M · CIK 0001546797 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 940,298

Read SEC document
November 16, 2021 Filed Nov 18, 2021 20:07 UTC CNS Pharmaceuticals, Inc. CNSP · Entity 8048 GrantCommon Stock 5,000 $1.28 $6,400.00
Disclosure

SEC source: 0001683168-21-005823 · ownership.xml · nonDerivative · entry 1

Climaco John M · CIK 0001546797 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 905,298

Read SEC document
June 07, 2021 Filed Jun 9, 2021 20:25 UTC Moleculin Biotech, Inc. MBRX · Entity 7886 GrantStock option (right to buy) · Derivative 10,000 Not disclosed Strike: $3.95 Not disclosed
Disclosure

SEC source: 0001437749-21-014427 · rdgdoc.xml · derivative · entry 1

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,168

Underlying: Common Stock · 10,000 shares

Expires 2031-06-07

F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company.

F1 · derivative.exercise_date: The options set forth in this table vest in four quarterly installments, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.

Read SEC document
February 05, 2021 Filed Feb 9, 2021 17:00 UTC CNS Pharmaceuticals, Inc. CNSP · Entity 8048 GrantOption to purchase common stock (right to buy) · Derivative 310,000 Not disclosed Strike: $3.36 Not disclosed
Disclosure

SEC source: 0001683168-21-000447 · ownership.xml · derivative · entry 1

Climaco John M · CIK 0001546797 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 749,500

Underlying: Common Stock · 310,000 shares

Expires 2031-02-05

F2 · price: The stock options were issued in connection with the reporting person's employment with the Company.

F1 · derivative.exercise_date: The stock options set forth in this table vest in four equal annual installments beginning on the first anniversary of the Transaction Date and are subject to the grantee's continued service to the Company on each vesting date.

Read SEC document
June 15, 2020 Filed Jun 17, 2020 20:32 UTC Moleculin Biotech, Inc. MBRX · Entity 7886 GrantStock option (right to buy) · Derivative 15,000 Not disclosed Strike: $1.12 Not disclosed
Disclosure

SEC source: 0001659617-20-000152 · wf-form4_159242592252592.xml · derivative · entry 1

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 15,000 shares

Expires 2030-06-15

F2 · price: (2) Issued in connection with the reporting person's employment with the Company.

F1 · derivative.exercise_date: (1) The options set forth in this table vest in four quarterly installments, subject to the grantee's continued service on the Company's Board of Directors in each vesting date.

Read SEC document
August 16, 2019 Filed Aug 19, 2019 16:19 UTC STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 GrantRestricted Stock Unit · Derivative 2,250 $0.00 $0.00
Disclosure

SEC source: 0000921895-19-002281 · form409271cli_08192019.xml · derivative · entry 2

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,250

Underlying: Common Stock · 2,250 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock.

F2 · derivative.exercise_date: One hundred percent (100%) of the Restricted Stock Units are scheduled to vest on the one (1) year anniversary of August 16, 2019, subject to the Reporting Person continuing to be a service provider through such date.

F2 · derivative.expiration_date: One hundred percent (100%) of the Restricted Stock Units are scheduled to vest on the one (1) year anniversary of August 16, 2019, subject to the Reporting Person continuing to be a service provider through such date.

Read SEC document
August 06, 2019 Filed Aug 8, 2019 16:41 UTC STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 Exercise / conversionRestricted Stock Unit · Derivative 1,250 Not disclosed Not disclosed
Disclosure

SEC source: 0000921895-19-002143 · form40927cli_08082019.xml · derivative · entry 2

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock.

F3 · derivative.exercise_price: This transaction represents the settlement of Restricted Stock Units in shares of common stock on their scheduled vesting date.

F1 · shares: On June 4, 2019, the Issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F2 · price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock.

F4 · derivative.exercise_date: On August 6, 2018 the Reporting Person was granted 12,500 Restricted Stock Units (prior to the Reverse Stock Split). As to this grant, 100% of the Restricted Stock Units fully vested on August 6, 2019.

F4 · derivative.expiration_date: On August 6, 2018 the Reporting Person was granted 12,500 Restricted Stock Units (prior to the Reverse Stock Split). As to this grant, 100% of the Restricted Stock Units fully vested on August 6, 2019.

F1 · derivative.underlying_shares: On June 4, 2019, the Issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

Read SEC document
August 06, 2019 Filed Aug 8, 2019 16:41 UTC STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 Exercise / conversionCommon Stock 1,250 Not disclosed Not disclosed
Disclosure

SEC source: 0000921895-19-002143 · form40927cli_08082019.xml · nonDerivative · entry 1

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,910

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On June 4, 2019, the Issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F2 · price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock.

F3 · price: This transaction represents the settlement of Restricted Stock Units in shares of common stock on their scheduled vesting date.

F1 · balance_after: On June 4, 2019, the Issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

Read SEC document
July 11, 2019 Filed Jul 15, 2019 20:14 UTC Moleculin Biotech, Inc. MBRX · Entity 7886 GrantStock option (right to buy) · Derivative 35,000 Not disclosed Strike: $1.31 Not disclosed
Disclosure

SEC source: 0001659617-19-000103 · wf-form4_156322163353261.xml · derivative · entry 1

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Common Stock · 35,000 shares

Expires 2029-07-11

F2 · price: (2) The options were issued in connection with the reporting person's Board of Director service to the Company.

F1 · derivative.exercise_date: (1) The options set forth in this table vest in four quarterly installments, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.

Read SEC document
May 22, 2019 Filed May 24, 2019 21:00 UTC Moleculin Biotech, Inc. MBRX · Entity 7886 GrantStock option (right to buy) · Derivative 15,000 Not disclosed Strike: $1.15 Not disclosed
Disclosure

SEC source: 0001144204-19-028197 · tv522433_4.xml · derivative · entry 1

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 15,000 shares

Expires 2029-05-22

F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company.

F1 · derivative.exercise_date: The options set forth in this table vest in four quarterly installments, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.

Read SEC document
March 15, 2019 Filed Mar 18, 2019 20:26 UTC STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 PurchaseCommon Stock 6,000 $0.82 $4,920.00
Disclosure

SEC source: 0000921895-19-000806 · form409271001cli_03182019.xml · nonDerivative · entry 1

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,600

Read SEC document
January 14, 2019 Filed Jan 14, 2019 16:52 UTC BIRNER DENTAL MANAGEMENT SERVICES INC BDMS · Entity 161087 Disposition to issuerCommon Stock 4,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-19-000996 · form4.xml · nonDerivative · entry 1

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Disposed of as a result of a merger pursuant to the previously announced Agreement and Plan of Merger, dated as of October 3, 2018 (the "Merger Agreement"), by and among the issuer, Mid-Atlantic Dental Services Holdings, LLC, and Bronco Acquisition, Inc., in exchange for, on a per share basis, (i) $10.62 in cash and (ii) a contingent value right entitling the holder thereof to receive up to $0.13 per share that may become payable after 18 months in accordance with the terms of the Merger Agreement.

F1 · price: Disposed of as a result of a merger pursuant to the previously announced Agreement and Plan of Merger, dated as of October 3, 2018 (the "Merger Agreement"), by and among the issuer, Mid-Atlantic Dental Services Holdings, LLC, and Bronco Acquisition, Inc., in exchange for, on a per share basis, (i) $10.62 in cash and (ii) a contingent value right entitling the holder thereof to receive up to $0.13 per share that may become payable after 18 months in accordance with the terms of the Merger Agreement.

Read SEC document
August 08, 2018 Filed Aug 8, 2018 19:33 UTC STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 Exercise / conversionRestricted Stock Unit · Derivative 12,500 Not disclosed Not disclosed
Disclosure

SEC source: 0000921895-18-002228 · form4cli09271004_08082018.xml · derivative · entry 3

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock.

F2 · derivative.exercise_price: This transaction represents the settlement of Restricted Stock Units in shares of common stock on their scheduled vesting date.

F1 · price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock.

F4 · derivative.exercise_date: On August 8, 2017 the Reporting Person was granted 12,500 Restricted Stock Units. As to this grant, 100% of the Restricted Stock Units fully vested on August 8, 2018.

F4 · derivative.expiration_date: On August 8, 2017 the Reporting Person was granted 12,500 Restricted Stock Units. As to this grant, 100% of the Restricted Stock Units fully vested on August 8, 2018.

Read SEC document
August 08, 2018 Filed Aug 8, 2018 19:33 UTC STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 Exercise / conversionCommon Stock 12,500 Not disclosed Not disclosed
Disclosure

SEC source: 0000921895-18-002228 · form4cli09271004_08082018.xml · nonDerivative · entry 1

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,600

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock.

F2 · price: This transaction represents the settlement of Restricted Stock Units in shares of common stock on their scheduled vesting date.

Read SEC document
August 06, 2018 Filed Aug 8, 2018 19:33 UTC STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 GrantRestricted Stock Unit · Derivative 12,500 $0.00 $0.00
Disclosure

SEC source: 0000921895-18-002228 · form4cli09271004_08082018.xml · derivative · entry 2

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock.

F3 · derivative.exercise_date: One hundred percent (100%) of the Restricted Stock Units are scheduled to vest on the one (1) year anniversary of August 6, 2018, subject to the Reporting Person continuing to be a service provider through such date.

F3 · derivative.expiration_date: One hundred percent (100%) of the Restricted Stock Units are scheduled to vest on the one (1) year anniversary of August 6, 2018, subject to the Reporting Person continuing to be a service provider through such date.

Read SEC document
June 20, 2018 Filed Jun 22, 2018 13:46 UTC BIRNER DENTAL MANAGEMENT SERVICES INC BDMS · Entity 161087 GrantCommon Stock 2,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-18-003078 · primarydocument.xml · nonDerivative · entry 1

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,000

F1 · shares: Restricted stock that vests in two equal installments on June 20, 2019 and June 20, 2020

Read SEC document
June 06, 2018 Filed Jun 8, 2018 21:27 UTC Moleculin Biotech, Inc. MBRX · Entity 7886 GrantStock option (right to buy) · Derivative 35,000 Not disclosed Strike: $1.82 Not disclosed
Disclosure

SEC source: 0001144204-18-033609 · tv496093_4.xml · derivative · entry 1

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 35,000 shares

Expires 2028-06-06

F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company.

F1 · derivative.exercise_date: The options set forth in this table vest in three equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service on the Companya(euro)(TM)s Board of Directors on each vesting date.

Read SEC document
August 08, 2017 Filed Aug 10, 2017 17:11 UTC STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 GrantRestricted Stock Unit · Derivative 12,500 $0.00 $0.00
Disclosure

SEC source: 0000921895-17-002087 · form409271cli_08102017.xml · derivative · entry 1

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock.

F2 · derivative.exercise_date: One hundred percent (100%) of the Restricted Stock Units are scheduled to vest on the one (1) year anniversary of August 8, 2017, subject to the Reporting Person continuing to be a service provider through such date.

F2 · derivative.expiration_date: One hundred percent (100%) of the Restricted Stock Units are scheduled to vest on the one (1) year anniversary of August 8, 2017, subject to the Reporting Person continuing to be a service provider through such date.

Read SEC document
August 02, 2017 Filed Aug 4, 2017 18:15 UTC STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 Exercise / conversionRestricted Stock Unit · Derivative 12,500 Not disclosed Not disclosed
Disclosure

SEC source: 0001193805-17-001417 · form409271cli_08042017.xml · derivative · entry 2

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock.

F2 · derivative.exercise_price: This transaction represents the settlement of Restricted Stock Units in shares of common stock on their scheduled vesting date.

F1 · price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock.

F3 · derivative.exercise_date: On August 2, 2016 the Reporting Person was granted 12,500 Restricted Stock Units. As to this grant, 100% of the Restricted Stock Units fully vested on August 2, 2017.

F3 · derivative.expiration_date: On August 2, 2016 the Reporting Person was granted 12,500 Restricted Stock Units. As to this grant, 100% of the Restricted Stock Units fully vested on August 2, 2017.

Read SEC document
August 02, 2017 Filed Aug 4, 2017 18:15 UTC STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 Exercise / conversionCommon Stock 12,500 Not disclosed Not disclosed
Disclosure

SEC source: 0001193805-17-001417 · form409271cli_08042017.xml · nonDerivative · entry 1

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,100

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock.

F2 · price: This transaction represents the settlement of Restricted Stock Units in shares of common stock on their scheduled vesting date.

Read SEC document
July 24, 2017 Filed Jul 27, 2017 01:06 UTC Moleculin Biotech, Inc. MBRX · Entity 7886 GrantOption to purchase common stock · Derivative 20,000 Not disclosed Strike: $1.87 Not disclosed
Disclosure

SEC source: 0001144204-17-038495 · v471461_4.xml · derivative · entry 1

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2027-07-24

F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company.

F1 · derivative.exercise_date: The options set forth in this table vest in three equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.

Read SEC document
June 20, 2017 Filed Jun 21, 2017 09:46 UTC BIRNER DENTAL MANAGEMENT SERVICES INC BDMS · Entity 161087 GrantCommon Stock 2,000 $0.00 $0.00
Disclosure

SEC source: 0001127602-17-021927 · form4.xml · nonDerivative · entry 1

Climaco John M · CIK 0001546797 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

F1 · shares: Restricted stock that vests in two equal installments on June 20, 2018 and June 20, 2019.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.